Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chunky volume like this indicates somebody is making a real bet. My guess: CEGE (some $$$$ but pipeline starved) will merge with another bio that is pipeline rich but out of funds.
Nice OTC PICKS we are in
OTCPicks.com Daily Market Movers Digest Midday Report for Friday, March
27th CAAH, ADDE, BRYN, KBLB, PTEK, ACTC, QTM, LJPC, CEGE, ANSV, GNBT,
UVSE
Our Stocks to Watch today include China America Holdings Inc. (OTCBB:
CAAH), Adoodle Inc. (OTC: ADDE), Bryn Resources Inc. (OTC: BRYN), Kraig
Biocraft Laboratories Inc. (OTCBB: KBLB), PokerTek Inc. (Nasdaq: PTEK),
Advanced Cell Technology Inc. (OTC: ACTC), Quantum Corp. (NYSE: QTM),
La Jolla Pharmaceutical Co. (Nasdaq: LJPC), Cell Genesys Inc. (Nasdaq:
CEGE), Anesiva Inc. (Nasdaq: ANSV), Generex Biotechnology Corp.
(Nasdaq: GNBT) and Universal Energy Corp. (OTCBB: UVSE).
Visit Newsletter and Email Stock Watch Alerts.
CHINA AMERICA HOLDINGS INCORPORATED (OTCBB: CAAH)
"Up 14.29% in morning trading"
In today .36's base on this news
BRIEF-Cell Genesys announces final results from phase 3 programBy: AFX | 27 Feb 2009 | 08:49 AM ET Text Size Feb 27 (Reuters) - Cell Genesys Inc: * Announces final results from phase 3 program of GVAX immunotherapy for prostate cancer * Says data suggest patients with Halabi predicted survival greater than or equal to 18 months may have more favorable response to immunotherapy ((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
This is just the beginning for CEGE's PPS . Should be ( will be ? ) trading in dollars .
Patience has paid off .
Renee
Renee and Howard. CEGE was part of the three dogs I've been holding; the other two are SPSN and GDIV. Maybe, they can enjoy a little life too. I like the President of CEGE and believe he will throw a few bucks our way. Chipwa1
Interesting I was right about the BIG WALL ST BOYS PLAYING HERE
The run up today is because 47 billion dollars worth of Genentech stock was turned into cash. That's why a boatload of biotechs went up the past couple of days. That's enough money to pay 100 million dollars for 50 biotechs. Those investors, if they pooled their money, could really buy 100 biotechs. Think about it, all that money is being redistributed as we speak. It could take weeks.
from cege yahoo bd
5.7 Mil shares Short! HMMMM 26-Mar-09 06:18 pm
What happens when buyers come into a low priced stock at the same the shorts start to cover. Look at CTIC today!
CEGE is still very cheap.
Re: GVAX Prostate Cancer Trial Results - To Be Presented 26-Mar-09 05:43 pm
http://guest.cvent.com/EVENTS/Info/Agend...
Tomorrow's 9:30 session.
I agree about Wall Street liking biotech that have life saving drugs in their portfolio . CEGE is my favorite , even though the other one went ballistic today .
Many I-HUBBER's think the stock world revolves around their support of a chosen stock . Clearly DEEP pockets moved both stocks as I-HUBBER's just stared at the headlights .
Pick a potentially good bio .....then wait for Wall Street to take the stock to where it belongs .
CEGE will have better days in the sunlight , IMO .
Renee
thanks for the compliment I was STUNNED how that other one you own moved today. You know the Wall St crowd is back in the biotech stocks again
Howard , you bring good karma to this board ....something intangible and nice .
Renee
Well , Chipwa , I cannot logically support my 6th sense about CEGE , but I have felt that CEGE was a $5.00 stock once they survived the financial doldrums the company experienced . They have done that .
Woman's intuition ? Well , that and their very solid drug pipeline .
I can wait as long as it takes .
Renee
Miss Lucky...care to foretell tomorrow and next week? I for one will be waiting and hanging on your every word. Honest! Chipwa1
Just call me Miss Lucky 2009 ....TWO home-runs in one day .
So ....that's what it feels like . Nice .
Renee
Well, as for me I'll hang in there. They only have a few people left in Hayward, where the top people remaining with the company moved too. I still feel the president will payout the shareholders, from all indications. The Japanese firm (Takada,sp?) in my opinion will pick up the technology, or maybe its American holding company. Chipwa1
Rats ....CEGE keeps drifting lower . I still sense that CEGE is a prime buy-out candidate for a premium .
The company is oddly silent when they should be critically concerned about their Nasdaq listing qualifications . Of course , if they are contemplating selling out then the Daq listing would be moot .
Sitting on a small mountain of CEGE shares .....GULP . Oh , right , never let them see ya sweat . Easier said than done .
Renee
Maybe-becouse-he-had-the-money-to-buy-it-hahaha, Thanks-for the info Chipwa1 Good one.
For L.C.KOPP to spend about $125,000 on CEGE you can surmise that he is exceptionally confident in CEGE's PPS going much higher .
Good info , Chipwa .
Renee
Leroy C. Kopp, B/O purchased 500,000 shares in five trade between February 19 and 25, 2009 at (0.25 & 0.26). Anyone have a clue why? Chipwa1
With a Current Ratio of 4.382, a book value of 0.286 and management that is shareholder oriented there is a good chance those holding this stock will see some upside after the surprise report on GVAX. The value of any sell off of technology should bring in a better price. Any comments? Chipwa1
I thought it was interesting to read that VGen has some merit in the test results Phase III. Which means to me that it will help selling the technology to its Japanese partner/investor, or other drug company. Any thoughts? Chipwa1
CEGE- GVAX ASCO abstracts...
Conclusion: It just didn't work.
VITAL1:
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20543
Background: A phase III trial comparing GVAX immunotherapy (CG1940/CG8711) to docetaxel plus prednisone was initiated in 2004. The study was designed to enroll 600 patients (pts) with a primary endpoint of superiority in overall survival. It was conducted at over 100 centers in North America and the European Union. The study was prematurely terminated based on the results of a previously unplanned futility analysis conducted by the study's independent Data Monitoring Committee (IDMC) which determined that the study had less than a 30% chance of meeting its predefined primary endpoint of improvement in overall survival. Methods: Castration-resistant, chemotherapy-naïve men without cancer-related pain requiring opioid analgesics were eligible. CG1940/CG8711 (500 million cells prime/300 million cells boost doses q 2 wks x 13 doses) was administered in the experimental arm (G) followed by maintenance GVAX immunotherapy (q 4 wks). Docetaxel (75mg/m2 q 3 wks x 9 cycles) plus prednisone (10 mg daily) was given in the control arm (D+P). Results: The study completed accrual of 626 patients in 2007, and all completed the initial 6 month treatment period. At the time of study termination the median follow-up was 66 weeks. Analysis of the dataset revealed no imbalance in patient baseline characteristics. The Halabi predicted survival (HPS) was 16 months for each arm. More than 45% of pts enrolled were Gleason > 8. The median number of doses was 8 (range 1-51) for G and 9 (1-16) for D+P. Grade 3 or higher related adverse events were 8.8% on G versus 43% on D+P. The median survival was 20.7 months on G and 21.7 months on D+P, hazard ratio 1.03, 95% CI (0.83, 1.28), p=0.78, stratified log-rank test. The Kaplan-Meier (KM) curve shows G crossing above D+P at approximately 22 months. In the subset of men with HPS > 18 months (n=264) median survival was prolonged on G (29.7 months) compared to D+P (27.1 months), HR 0.90 (0.61-1.33), p=0.60.Conclusions: This randomized phase III trial shows that the toxicity profile of GVAX is favorable compared to D+P. While survival was not significantly improved overall compared to chemotherapy, a late favorable effect of GVAX is suggested by crossover in the KM survival curve. Pts with HPS >= 18mo may have a more favorable response to immunotherapy.
VITAL2:
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20295
A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC)
ntroduction: A phase III trial comparing GVAX immunotherapy for prostate cancer in combination with docetaxel to docetaxel plus prednisone was initiated in 2005. The study was designed to enroll 600 patients (pts) with a primary endpoint of superiority in overall survival. It was conducted at over 100 centers in North America and the European Union. Methods: Pts with taxane-naïve CRPC with pain requiring opioid analgesics were eligible. Docetaxel (75 mg/m2 q 3 wks x 10 cycles) was given in both arms. Prednisone (10 mg daily) was given in the control arm (D+P). CG1940/CG8711 (500 million cells prime/300 million cells boost doses q 3 wks x 10 cycles) was administered 2 days following each docetaxel infusion in the experimental arm (D+G) followed by maintenance immunotherapy alone (q 4 wks). Results: The study was prematurely terminated after accrual of 408 pts due to an imbalance in deaths, with 67 deaths in the D+G arm and 47 deaths in the D+P arm. The preliminary analysis revealed no imbalance in pt baseline characteristics. Median predicted survival based on the Halabi prognostic factor nomogram was 13 months in both arms. Fewer cycles of docetaxel were received in the D+G arm (median of 5 vs. 7, p = 0.0100, Wilcoxon Rank-Sum test). Fewer pts in the D+G arm completed all 10 cycles (27 vs. 37 percent, p = 0.0116, chi-square test). No significant toxicities in the D+G arm were observed that could explain the imbalance in deaths. 85% of deaths were reported as due to prostate cancer in both arms. The imbalance was restricted to deaths from prostate cancer and to pts with evidence of PSA progression at time of death. Overall survival was shorter in the D+G arm with median survival of 12.2 months, vs. 14.1 months in the D+P arm (hazard ratio 1.70, 95% CI [1.15, 2.53], p = 0.0076 per stratified log-rank test). Conclusions: Preliminary analysis of this prematurely terminated trial demonstrated a survival advantage for the control arm, D+P over the experimental arm D+G. No unexpected safety issues were identified. Exploratory analyses to identify subgroups of pts with preferential benefit from the investigational therapy are underway.
I've noticed the same. Volume had been anemic lately but has been more like 500,000-1000000 (didn't look it up) this week. Presumably year-end financials need to come out soon and maybe some greater clarity is postulated to be given at that point
Not that I'm trying to beat a dead house, but the stock has been acting a little strange the last two weeks. It seems to be showing some strength to the upside, in this gloomy market. My thoughts are someone is trying to buy up shares without driving the stock up and that it may be a buyer. Only thing wrong with that idea volume is to low. Any other thoughts out there?
Chipwa1
Short interest almost 7 millions shares.. would be nice to cause a short squeeze? right? i know some of you have deep pockets!
GLLs
Schedule 13D/A filed on January 16th . Link attached herein :
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=6350382-1342-27294&type=sect&TabIndex=2&companyid=10481&ppu=%252fdefault.aspx%253fcik%253d865231
KOPP Investments now owns 9.15 % of CEGE's Outstanding Shares .
Renee
Chart looking nice.
$$$$
Well I'm mustering all the positive noise I can, with CEGE crawling along the bottom. Been here in Waikoloa Beach (on the Big Island) since December 13. Just about ready to go home. I'm so ready for the stock to make a "BIG" move. Wishing you all health and happiness in 2009. Chipwa1
Why yes indeed , CEGE is " strong like Bull " , as I talk to myself .
I'm beginning to feel like the Maytag Repairman on this board , singing Bobby Vinton's Mr. Lonely ....sung with my squeaky voice , hahaha .
Oh oh ...I'm talkin' to myself again .....ahhhhhhhh , the voices in my head .
GO CEGE GOOOOOOOOOOOOO .
Shut up Renee .
OK , I will , Renee .
Nice. The Hilton :). The market must have been good to you. What is the latest on Cell Genesys?
News : Cell Genesys Announces Results of its Modified Dutch Auction Tender Offer :
Wednesday December 17, 8:30 am ET
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cell Genesys, Inc. (NASDAQ:CEGE - News) today announced the results of its “Modified Dutch Auction” tender offer for a portion of its outstanding 3.125% Convertible Senior Notes due 2011. The offer expired at 5:00 p.m., ET, on Tuesday, December 16, 2008.
In accordance with the terms and conditions of the tender offer, and based on the count by U.S. Bank National Association, the depositary for the tender offer, Cell Genesys expects to accept for payment approximately $47.8 million aggregate principal amount of convertible notes at a purchase price of $400 per $1,000 principal amount, for a total cost of approximately $19.1 million (excluding accrued interest and fees and other expenses in connection with the tender offer).
Based on the count by the depositary, approximately $47.8 million aggregate principal amount of convertible notes were properly tendered and not withdrawn in the tender offer. Holders of convertible notes who properly tendered their convertible notes in the tender offer at or below the purchase price will have all of their tendered convertible notes accepted for payment.
The aggregate principal amount of convertible notes that Cell Genesys will purchase represents approximately 40% of its currently outstanding principal amount of convertible notes.
In the tender offer, Cell Genesys offered to purchase, for cash, up to $80 million aggregate principal amount, or up to approximately 67%, of its outstanding convertible notes at a price not greater than $400 nor less than $340, per $1,000 principal amount, plus accrued and unpaid interest thereon up to, but not including, the date of purchase of the convertible notes. The maximum aggregate purchase price for the convertible notes that Cell Genesys sought to purchase in the tender offer was $32 million, plus accrued and unpaid interest.
The dealer manager for the tender offer is Lazard Capital Markets LLC. The depositary for the tender offer is U.S. Bank National Association and the information agent for the tender offer is Georgeson Inc. Holders of convertible notes who have questions about the tender offer may call the information agent at (866) 206-4938. Banks and brokerage firms may call (212) 440-9800.
Hello from the Hilton, Waikoloa, the Big Island. Wishing all health and happiness in the New Year. Chipwa1
My father was full blood Ojibwa (Nation)/Chippewa (Tribe). Jumped in late October this year, after selling out completely last October 2007. In hind sight I got back in a little to early, in the hole about 25% currently, but I am holding good stocks for the recovery. Chipwa1
Good take! will consider stepping in! u have a convincing argument.... but keep in mind this SOX even screwed japanesse.. remember..? where else r u parking nowadays? why do you nickname yourself chipo? just wanna get an idea about your investing/trading style?
tia
GL2U
By-the-way, the 17,600 shares traded at the asking price, and for every buyer there is a seller, so you can flip a coin.
chipwa1
I just said; nice to see the large block at the end of the day. That said: With 100-150 million in cash at the end of the year and assets to sell; I would think the company might funnel some of that cash back to shareholders. The CEO gives every indication of being shareholder oriented. I'll just wait it out. I never have sold short, or gone on margins for what its worth. Chipwa1
how do you know it is a buy? not short covering?
GL
Nice to see the Buy at 0.32; 17,600 around the close. I think somehow shareholders will get a piece of the pie down the road. Chipwa1
japan quits supporting!
Cell Genesys and Takeda terminate collaboration agreement
Thursday December 04, 2008 09:38:41 EST
Dec 04, 2008 (Datamonitor via COMTEX News Network) --
Cell Genesys, a biotechnology company, and Takeda Pharmaceutical Company, together with its wholly owned subsidiary Millennium Pharmaceuticals, have mutually agreed to suspend the further development of Gvax immunotherapy for prostate cancer.
Takeda has also ended the collaboration agreement with Cell Genesys for the development and commercialization of the product.
Under the terms of the agreement, Takeda will return all commercial rights to Gvax immunotherapy for prostate cancer to Cell Genesys and make certain wind-down payments to Cell Genesys in connection with the phasing out of the remaining clinical development activities.
More fund buying Friday
http://www.mffais.com/cege.html
Agree huge buy opp. at these prices
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
889
|
Created
|
07/22/07
|
Type
|
Free
|
Moderators |
http://www.cellgenesys.com/home.shtml
http://finance.yahoo.com/q/ks?s=CEGE
http://moneycentral.msn.com/ownership?Symbol=CEGE
Cell Genesys, Inc., a biotechnology company, engages in development and commercialization of biological therapies for cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company's clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. Its GVAX cancer Immunotherapies include Prostate Cancer, a phase 3 product for the treatment of prostate cancer; Pancreatic Cancer, a phase 2 product for pancreatic cancer; and Leukemia, a phase 2 product for the treatment of acute myelogenous leukemia and chronic myelogenous leukemia. The company's Oncolytic Virus Therapy includes CG0070, a phase 1 product for the treatment of recurrent bladder cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Amgen, Inc. The company was founded in 1988 and is headquartered in South San Francisco, California. Feel for you folks, sincerely.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |